Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35257363.
- Also identified by DOI 10.1111/bjd.21233.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.
Medical subject headings
- Arthritis, Psoriatic
- Nail Diseases
- Nails, Malformed
- Psoriasis